AKRIMAX Pharmaceuticals Announces Manufacturing Partnership
Signs Agreement with Global Healthcare Company
January 06, 2009 – Rouses Point, NYAkrimax Pharmaceuticals, LLC announced today a manufacturing agreement for the production of pharmaceutical products for a global company beginning in 2009. Akrimax was selected from several potential partners in a competitive process.
Akrimax President Alan L. Rubino said: “this agreement further validates Akrimax’s decision to acquire the Rouses Point facility which possesses, diverse manufacturing and packaging capabilities, and a spotless regulatory and safety record. We are pleased to announce this development as we are ahead of our planned schedule of bringing in new manufacturing partnerships to our Rouses Point facility.”
Rubino also said: “Our contract manufacturing partnership enhances our strategic plan and showcases the quality of our people and our ability to execute at this facility. We are proving every day that Made in America pharmaceutical manufacturing is good business for our partners because of our high-quality manufacturing, competitive value and excellent track record with the FDA.”
About Akrimax
Akrimax Pharmaceuticals, LLC is a privately-held, fully-integrated next-generation specialty pharmaceutical company that acquires, markets and develops products to
address disease states related to metabolic diseases. The company also owns a world-class manufacturing plant in Rouses Point, NY with a highly skilled workforce.
The plant encompasses 67.6 acres with 38 buildings, offering approximately 1 million sq. feet of manufacturing and packaging space. Akrimax was formed in 2007 and
purchased the Rouses Point plant from Wyeth in January 2008.
Based in Cranford, NJ, Akrimax pursues unsurpassed quality in the development, production, manufacturing, distribution, and commercialization of a full range of top-quality pharmaceutical products.
For more information:
www.Akrimax.com
Timothy Soule: tsoule@akrimax.com
Kevin Ellis: Kimbell Sherman Ellis: 800-498-5390 ext. 107: Kevin@kse50.com
